Portal de Periódicos da CAPES

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure

2013; Oxford University Press; Volume: 35; Issue: 14 Linguagem: Inglês

10.1093/eurheartj/eht302

1522-9645

Jochen Springer, Anika Tschirner, Arash Haghikia, Stephan von Haehling, Hind Lal, Aleksandra Grzesiak, Elena Kaschina, Sandra Palus, Mareike S. Pötsch, Karoline von Websky, Berthold Hocher, Céline Latouche, Frédéric Jaisser, Lars Morawietz, Andrew J.S. Coats, John Beadle, Josep M. Argilés, Thomas Thum, Gábor Földes, Wolfram Doehner, Denise Hilfiker‐Kleiner, Thomas Force, Stefan D. Anker,

Mitochondrial Function and Pathology

Symptoms of cancer cachexia (CC) include fatigue, shortness of breath, and impaired exercise capacity, which are also hallmark symptoms of heart failure (HF). Herein, we evaluate the effects of drugs commonly used to treat HF (bisoprolol, imidapril, spironolactone) on development of cardiac wasting, HF, and death in the rat hepatoma CC model (AH-130). Tumour-bearing rats showed a progressive loss of body weight and left-ventricular (LV) mass that was associated with a progressive deterioration in cardiac function. Strikingly, bisoprolol and spironolactone significantly reduced wasting of LV mass, attenuated cardiac dysfunction, and improved survival. In contrast, imidapril had no beneficial effect. Several key anabolic and catabolic pathways were dysregulated in the cachectic hearts and, in addition, we found enhanced fibrosis that was corrected by treatment with spironolactone. Finally, we found cardiac wasting and fibrotic remodelling in patients who died as a result of CC. In living cancer patients, with and without cachexia, serum levels of brain natriuretic peptide and aldosterone were elevated. Systemic effects of tumours lead not only to CC but also to cardiac wasting, associated with LV-dysfunction, fibrotic remodelling, and increased mortality. These adverse effects of the tumour on the heart and on survival can be mitigated by treatment with either the β-blocker bisoprolol or the aldosterone antagonist spironolactone. We suggest that clinical trials employing these agents be considered to attempt to limit this devastating complication of cancer.